Clearside Biomedical (NASDAQ:CLSD) just reported results for the second quarter of 2024.
- Clearside Biomedical reported earnings per share of -10 cents. This was above the analyst estimate for EPS of -13 cents.
- The company reported revenue of $90,000.
- This was 40% worse than the analyst estimate for revenue of $150,000.